Clinical trial
Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily…
NCT00262522 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00262522 |
|---|---|
| Title | Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects |
| Official title | A Phase 3, Randomized, Open-label, Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With NRTIs in Antiretroviral Naive HIV-1 Infected Subjects |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Human Immunodeficiency Virus Infections |
| Intervention type | Drug |
| Interventions | lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs) |
| Enrollment | 664 |
| Start date | Nov 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Dec 7, 2005 |
| Last update posted | Feb 6, 2012 |
| Countries | Australia, Belgium, Canada, Czechia, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Puerto Rico and 7 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: